Navigation Links
Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
Date:4/22/2013

Durham, NC (PRWEB) April 22, 2013

Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the issuance of three new patents. Two of the newly released patents cover monoclonal antibodies to progastrin and have been issued in the United States and Australia. The third patent is for a companion diagnostic immunoassay issued in Canada which was previously issued earlier in the year for the United States. Collectively, these patents are additive parts to Cancer Advances’ suite of products that work to inhibit the cancer causing hormone, gastrin 17.

Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.

The two progastrin patents cover a pharmaceutical composition, comprised of a progastrin-binding molecule that selectively binds to progastrin, a monoclonal antibody to progastrin, and an immunoassy to determine the amount of progastrin in a sample. These patents also cover a method of monitoring treatment of a gastrin-promoted disease or by determining the level of progastrin in a patient.

The third patent, which covers a companion diagnostic immunoassay, is used for the detection and quantitation of gastrin hormones found in a biological fluid sample such as blood. It allows oncologists to identify and target patients who will receive the greatest benefit from treatment with PAS. Slowing tumor growth, improving quality of life, and extending survival for patients suffering from a gastrin hormone-mediated disease are all accomplishments that Cancer Advances has continually strived toward in its research.

“Cancer Advances continues to produce products that progress our efforts in the fight against gastrin-related diseases,” says Lynda Sutton, president of Cancer Advances.

For more information, please contact:
Lynda Sutton
President, Cancer Advances
lsutton(at)cato(dot)com
919-361-2162
http://www.canceradvancesinc.com

About Cancer Advances
Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html

# # #

Read the full story at http://www.prweb.com/releases/2013/4/prweb10630275.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... , ... September 01, 2020 , ... ... sciences, biotechnology, and diagnostics companies, has announced the placement of Julianne Averill ... be responsible for leading all financial operations and implementing key business strategies to ...
(Date:8/12/2020)... (PRWEB) , ... August 11, 2020 , ... ... a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network ... 2021 and 2022. The network is a consortium of academic research centers in ...
(Date:8/3/2020)... ... August 03, 2020 , ... ERT, the ... CEO has been named one of the 100 most inspiring individuals in the ... honorees are selected based on how they have inspired their colleagues and affected ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has ... be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar ... switches in a push-pull configuration; yielding fast fall time for a capacitive load. ...
Breaking Biology Technology:
(Date:7/22/2020)... , ... July 21, 2020 , ... ... transformation and innovation in technology and compliance, announces a new solution to manage ... must ensure every layer of their technology stack complies with FDA and global ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient MasterClass ... is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of savory ... at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting & ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader ... Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. ... in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply ...
Breaking Biology News(10 mins):